🚀 VC round data is live in beta, check it out!
Cynata Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cynata Therapeutics and similar public comparables like Aligos Therapeutics, Cessatech, Scilex Holding, Xilio Therapeutics and more.
Cynata Therapeutics Overview
About Cynata Therapeutics
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Founded
2003
HQ
Employees
2
Website
Sectors
Financials (LTM)
EV
$47M
Cynata Therapeutics Financials
Cynata Therapeutics reported last 12-month revenue of $10M and negative EBITDA of ($11M).
In the same LTM period, Cynata Therapeutics generated $10M in gross profit, ($11M) in EBITDA losses, and had net loss of ($12M).
Revenue (LTM)
Cynata Therapeutics P&L
In the most recent fiscal year, Cynata Therapeutics reported revenue of — and net income of —.
Cynata Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $10M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($11M) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (118%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (120%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($12M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (119%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cynata Therapeutics Stock Performance
Cynata Therapeutics has current market cap of $48M, and enterprise value of $47M.
Market Cap Evolution
Cynata Therapeutics' stock price is $0.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47M | $48M | 1.2% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCynata Therapeutics Valuation Multiples
Cynata Therapeutics trades at 4.8x EV/Revenue multiple, and (4.1x) EV/EBITDA.
EV / Revenue (LTM)
Cynata Therapeutics Financial Valuation Multiples
As of April 10, 2026, Cynata Therapeutics has market cap of $48M and EV of $47M.
Equity research analysts estimate Cynata Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cynata Therapeutics has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV (current) | $47M | XXX | $47M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (4.1x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (4.0x) | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | — | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | — | XXX | XXX | XXX |
| EV/FCF | (4.4x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cynata Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cynata Therapeutics Margins & Growth Rates
Cynata Therapeutics' revenue in the last 12 month grew by 40%.
Cynata Therapeutics' rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cynata Therapeutics' rule of X is 165% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cynata Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | 387% | XXX | XXX | XXX |
| EBITDA Margin | (118%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (38%) | XXX | 26% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 165% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 191% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cynata Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aligos Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cessatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Scilex Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Xilio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vicapsys | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cynata Therapeutics M&A Activity
Cynata Therapeutics acquired XXX companies to date.
Last acquisition by Cynata Therapeutics was on XXXXXXXX, XXXXX. Cynata Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cynata Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCynata Therapeutics Investment Activity
Cynata Therapeutics invested in XXX companies to date.
Cynata Therapeutics made its latest investment on XXXXXXXX, XXXXX. Cynata Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cynata Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cynata Therapeutics
| When was Cynata Therapeutics founded? | Cynata Therapeutics was founded in 2003. |
| Where is Cynata Therapeutics headquartered? | Cynata Therapeutics is headquartered in Australia. |
| How many employees does Cynata Therapeutics have? | As of today, Cynata Therapeutics has over 2 employees. |
| Is Cynata Therapeutics publicly listed? | Yes, Cynata Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Cynata Therapeutics? | Cynata Therapeutics trades under CYP ticker. |
| When did Cynata Therapeutics go public? | Cynata Therapeutics went public in 2007. |
| Who are competitors of Cynata Therapeutics? | Cynata Therapeutics main competitors are Aligos Therapeutics, Cessatech, Scilex Holding, Xilio Therapeutics. |
| What is the current market cap of Cynata Therapeutics? | Cynata Therapeutics' current market cap is $48M. |
| What is the current revenue of Cynata Therapeutics? | Cynata Therapeutics' last 12 months revenue is $10M. |
| What is the current revenue growth of Cynata Therapeutics? | Cynata Therapeutics revenue growth (NTM/LTM) is 40%. |
| What is the current EV/Revenue multiple of Cynata Therapeutics? | Current revenue multiple of Cynata Therapeutics is 4.8x. |
| Is Cynata Therapeutics profitable? | No, Cynata Therapeutics is not profitable. |
| What is the current EBITDA of Cynata Therapeutics? | Cynata Therapeutics has negative EBITDA and is not profitable. |
| What is Cynata Therapeutics' EBITDA margin? | Cynata Therapeutics' last 12 months EBITDA margin is (118%). |
| What is the current EV/EBITDA multiple of Cynata Therapeutics? | Current EBITDA multiple of Cynata Therapeutics is (4.1x). |
| What is the current FCF of Cynata Therapeutics? | Cynata Therapeutics' last 12 months FCF is ($11M). |
| What is Cynata Therapeutics' FCF margin? | Cynata Therapeutics' last 12 months FCF margin is (109%). |
| What is the current EV/FCF multiple of Cynata Therapeutics? | Current FCF multiple of Cynata Therapeutics is (4.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.